| Literature DB >> 17502863 |
Asifa S Haider1, Irma R Cardinale, Julia A Whynot, James G Krueger.
Abstract
Proinflammatory diseases like rheumatoid arthritis, Crohn's disease, and psoriasis have been treated by the tumor necrosis factor (TNF) antagonists infliximab and etanercept with different degrees of success. Although these agents are widely used in humans, little is known about their mechanisms of action or why etanercept and infliximab have differences in clinical activity. In this study, we define leukocyte genes that are suppressed by etanercept within 24 hours of exposure. Compared to previous work with infliximab, fewer immune-related genes are suppressed by etanercept. Importantly, the range of genes suppressed by these alternative TNF inhibitors is only partially overlapping, suggesting each has unique immune modulating effects. In sharp contrast to etanercept, infliximab strongly suppresses genes associated with "Type 1" immune responses (IFN-gamma and the IL-12-receptor beta 2 subunit), providing a clear mechanism for clinically relevant immune suppression.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17502863 DOI： 10.1038/sj.jidsymp.5650032
Source DB: PubMed Journal: J Investig Dermatol Symp Proc ISSN： 1087-0024